Rydex Health Care C holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Rydex Health Care Fund Class C RYHCX
- NAV / 1-Day Return 103.80 / +0.14 %
- Total Assets 21.7M
-
Adj. Expense Ratio
2.400%
- Expense Ratio 2.400%
- Distribution Fee Level High
- Share Class Type Level Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.00
- Turnover 244%
USD | NAV as of Oct 03, 2026 | 1-Day Return as of Oct 03, 2026, 12:11 AM GMT+0
Morningstar’s Analysis RYHCX
Will RYHCX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 24.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 4.07 | 796,146 | Healthcare |
Johnson & Johnson | 3.40 | 665,741 | Healthcare |
AbbVie Inc | 2.94 | 575,405 | Healthcare |
UnitedHealth Group Inc | 2.59 | 506,811 | Healthcare |
Merck & Co Inc | 2.42 | 473,147 | Healthcare |
Thermo Fisher Scientific Inc | 2.15 | 420,962 | Healthcare |
Amgen Inc | 1.94 | 378,997 | Healthcare |
Abbott Laboratories | 1.93 | 377,560 | Healthcare |
Gilead Sciences Inc | 1.67 | 327,218 | Healthcare |
Bristol-Myers Squibb Co | 1.61 | 315,774 | Healthcare |